The Cancer Epidemiology Program (CEP) brings together 25 investigators from 11 Departments at Stanford and the Northern California Cancer Center (NCCC) in a collaborative approach to reducing the burden, incidence, mortality and morbidity of cancer through innovative and interdisciplinary epidemiologic research. This goal is accomplished through observational research in four areas: cancer surveillance;cancer etiology and risk assessment;early cancer detection;and cancer treatment, prognosis and quality of life. The study of disparities among racial/ethnic/cultural groups forms a theme cross cutting all of these areas.
The specific aims of the four targeted research areas are: ? Cancer surveillance: Describe cancer risk factors and spatial and temporal trends in cancer incidence and mortality;identify scientific hypotheses for further study;conduct methodologic studies to improve data quality;and gather data as new technologies and treatments are introduced into medical practice. ? Cancer etiology and risk assessment: Convene multidisciplinary expertise to study the complex interactions of molecular, genetic, behavioral and environment factors that affect cancer occurrence. ? Early detection of cancer: Evaluate the use of new technologies to detect cancers before they have spread and increase understanding of the risks and benefits of screening. ? Cancer care, prognosis and quality of life: Conduct observational studies of cancer treatments and other cancer care to determine their diffusion, utilization and effect on patient outcomes by characteristics of patients, providers and delivery systems. Identify genetic, molecular and other determinants of recurrence and survival in cancer patients, and factors related to quality of life for cancer patients and families.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA124435-07
Application #
8475451
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
7
Fiscal Year
2013
Total Cost
$15,591
Indirect Cost
$4
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Pollom, Erqi L; Fujimoto, Dylann K; Han, Summer S et al. (2018) Newly diagnosed glioblastoma: adverse socioeconomic factors correlate with delay in radiotherapy initiation and worse overall survival. J Radiat Res 59:i11-i18
Nørgaard, Caroline Holm; Jakobsen, Lasse Hjort; Gentles, Andrew J et al. (2018) Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study. PLoS One 13:e0193249
Im, Hogune; Rao, Varsha; Sridhar, Kunju et al. (2018) Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cells. Leuk Lymphoma 59:2952-2962
Huang, Min; Zhu, Li; Garcia, Jacqueline S et al. (2018) Brd4 regulates the expression of essential autophagy genes and Keap1 in AML cells. Oncotarget 9:11665-11676
Chiou, Shin-Heng; Dorsch, Madeleine; Kusch, Eva et al. (2018) Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. Sci Rep 8:14008
Breslow, David K; Hoogendoorn, Sascha; Kopp, Adam R et al. (2018) A CRISPR-based screen for Hedgehog signaling provides insights into ciliary function and ciliopathies. Nat Genet 50:460-471
Chu, Lisa W; Till, Cathee; Yang, Baiyu et al. (2018) Circadian genes and risk of prostate cancer in the prostate cancer prevention trial. Mol Carcinog 57:462-466
Patel, Manali I; Sundaram, Vandana; Desai, Manisha et al. (2018) Effect of a Lay Health Worker Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With Cancer: A Randomized Clinical Trial. JAMA Oncol 4:1359-1366
Trieu, Vanessa; Pinto, Harlan; Riess, Jonathan W et al. (2018) Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck. Oncologist 23:764-e86
Kuonen, François; Surbeck, Isabelle; Sarin, Kavita Y et al. (2018) TGF?, Fibronectin and Integrin ?5?1 Promote Invasion in Basal Cell Carcinoma. J Invest Dermatol 138:2432-2442

Showing the most recent 10 out of 322 publications